IGI Logo
Toggle Navigation
News
Hindi
Hindi News
Top News
Screeners
Stocks
Stocks Screener
Stock
News
Stock Market Home Page
Stock News
Industry News
Economy News
Stock on the move
Expert Views
Research Reports
Company Result
Comp Info And Fundamentals
Company Profile
Equity
Financial Ratios
Results
Balance Sheet
Profit And Loss
Cash Flow
Share Holding
Derivatives (F&O)
Get Quotes
Market Watch
Top Gainers
Top Losers
Top Traded Quantity
Top Traded Value
Most Active Puts
Derivatives (F&O)
Most Active Calls
Put Call Ratio
Highest In Premium
Daily Settlement Price
FII and DII Statistics
Open Interest: Highest In OI
Open Interest: Lowest In OI
Derivatives (F&O)
Open Interest: Increase in OI Increase in Price
Open Interest: Decline in OI Decrease in Price
Derivative Watch
Derivatives Dashboard
Historical Data
List of Underlyings & Underlying Info
Derivative Watch
Derivatives Dashboard
Market Reports
Top Gainers
Top Losers
Monthly High/Low
52 Week High
52 Week Low
Market Cap Gainers
Market Cap Losers
PE Ratio
>More Market Reports
IPO
News
IPO News
IPO Issue Reports
Commodity
Commodity Market
Commodity Home Page
Commodity News
Commodity Reports
Market Details
Get Quotes
Top Gainers
Top Losers
Top Volume
Top Value
Top Gainers Spot Market
Top Losers Spot Market
High & Low
Commodity Indices
Technical Analysis
Advance Declines
High & Low
Highest In OI
Lowest OI
Increase In Open Interest(%)
Descrease In Open Interest(%)
Currency
News
Currency News
Economy News
Currency Reports
Mutual Fund
News
Mutual Fund Home Page
Mutual Fund News
Mutual Fund Details
Mutual Fund Home Page
Compare Scheme
Scheme Profile
Mutual fund Investment
Mutual Fund Share Holding
Mutual Fund Statistics
Mutual fund Gainers
Mutual fund Losers
Biggest Schemes
Best Performers
Latest Dividend Details
Tools
Multi Scheme Comparison Tool
Dividend Details
Performance Map
Mutual fund Investment
Mutual fund Share Holding
Mutual Fund Search Category Rankings
Widgets
Stock Widgets
Watchlist
Heatmap
Mutual Fund Widgets
Watchlist
Calculators
EMI Calculator
SIP Calculator
SWP Calculator
GST Calculator
FD Calculator
RD Calculator
Wealth
World
Tips
Intraday Tips
Market Outlook
Stock Tips
Commodity Tips
Currency Tips
Reports
Short Term Investment Opportunities
Long Term Investment Opportunities
Sector Analysis
Commodity Reports
Currency Reports
Mutual Fund Analysis
Podcast
Videos
Videos Category
Business Videos
Budget Videos
News And Politics
Entertainment Videos
Sports Videos
Lifestyle And Fashion Videos
Global News Videos
Calculators
EMI Calculator
SIP Calculator
SWP Calculator
GST Calculator
FD Calculator
RD Calculator
More
Budget 2024
Astrology
Women
Politics
Entertainment
Car&Bike
Gadgets
Lifestyle
Sports
Health
Fashion
Diwali Reports
Diwali Expert Reports
News
Astrology
Beyond Market Car
Beyond Market Entertainment
Beyond Market Fashion
Beyond Market Gadgets
Beyond Market Health
Beyond Market India
Beyond Market Life Style
Beyond Market Sports
Broking Firm Views
Broking Firm Views - Long Term Report
Broking Firm Views - Sector Report
Broking Firm Views - Short Term Report
Budget 2024 Sector Reports
Budget Bites
Budget Economic Servey
Budget Expert Views
Budget Industry
Budget News
Budget Wishlist
Commodities
Commodities Reports
Commodity Top News
Company News
Company Result
Currency News
Currency Report
Currency Top News
Diwali Expert Views
Diwali Market Outlook
Diwali Report
Diwali Technical Report
Economy News
Expert View Institution
Expert Views
Industry News
IPO Analysis
IPO More News
IPO Reports
IPO Top News
Market Outlook
Mutual Fund Analysis
Mutual Fund Expert Views
Mutual Fund More News
Mutual Fund Top News
Podcast - Market Ki Awaaz
Special Event Expert Views
Special Event Reports
Startup
Startup Expections
Startup Speak
Stock Market
Stock On The Move
Top News
Top Stories
Videos
Videos Business
Videos Entertainment
Videos Global News
Videos Lifestyle And Fashion
Videos News And Politics
Videos Sports
Wealth
Women
World Market More News
World Top News
Search
Zydus Wellness is currently trading at Rs. 1491.00, up by 9.00 points or 0.61% from its previous closing of Rs. 1482.00 on the BSE. The scrip opened at Rs. 1498.00 and has touched a high and low of Rs. 1498.00 and Rs. 1475.70 respectively. So far 889 shares were traded on the counter. The BSE group 'A' stock of face value Rs. 10 has touched a 52 week high of Rs. 1791.15 on 02-Nov-2022 and a 52 week low of Rs. 1363.85 on 02-Feb-2023. Last one week high and low of the scrip sto...
Zydus Wellness gains on reporting 9% rise in Q4 consolidated net profit
A forgettable quarter in terms of margins while focus continues on laying building blocks Zydus reported a decent (though below potential) top-line and volume growth prints of 12% and 5%, respectively. Gross margins were down 490bps YoY due to sharp inflation in milk prices and weak product mix. Continued brand investments and higher other opex lead to dismal EBITDA margin print of 3.8%. We note that Zydus probably has higher distribution expansion benefit (compared to peers), which is not...
Buy Zydus Wellness Ltd For Target Rs.2,000 - ICICI Securities
Strong recovery led by summer brands About the stock: Zydus Wellness (ZWL) is one of the FMCG companies present in healthcare, nutrition & related products. The company has six brands i.e. Sugarfree, Complan, Glucon-D, Nycil, Everyuth & Nutrilite * It commands dominant market share in Sugar substitute (96%), Prickly heat powder (34.2%) & Glucose powder (60.4%) categories * The company has more than 850 distributors with direct reach of 0.6 million retail outlets. Its high...
Buy Zydus Wellness Ltd For Target Rs.2100 - ICICI Direct
Improved quarter performance led by market share gains; maintain ADD Our view Q1 performance was quite encouraging on the growth fronts led by 10.3% volume growth and sequential market share gains in key brands GluconD, Nycil and Everyuth. Complan and Sugar Free continue to struggle since last few quarters due to category decline and less aggression in distribution expansion. Timely price hikes in Q4 also aided gross margin contraction to only 110bps. Few positives were strong double di...
Add Zydus Wellness Ltd For Target Rs.1,858 - Yes Securities
Zydus Wellness Ltd. (ZWL) recently announced its performance for the quarter ended June 30, 2022. The company posted a healthy set of numbers backed by strong growth in summer season brands Glucon-D & Nycil, coupled with price rises. Following are the key highlights. Highlights from Q1 FY23 * During the quarter, the top-line grew by 16.6% YoY to Rs.696.8 cr; on sequential basis, the turnover jumped 8.9% QoQ; the net sales recorded an increase of 17.8% (volume growth 10.3%). * Acc...
Buy For Zydus Wellness Ltd Target Rs.2,520 - Sushil Finance
Zydus Wellness Ltd. (ZWL) recently announced its performance for the quarter ended March 31, 2022. The top-line & EBITDA were in-line with our estimates & bottom-line was moderately above our estimate. Following are the key highlights. Highlights from Q4 FY22 & FY22 * During the quarter, the top-line grew by 5.6% (volume growth 0.4%) and during the fiscal ended March 31, 2022, the top-line grew by 7.3% (volume growth 2.3%). The Management stated that the company has taken a ...
Buy For Zydus Wellness Ltd Target Rs.2,520 - Sushil Finance
Add For Zydus Wellness Ltd Target Rs.1,858 Weakness persists on both growth and margin fronts; downgrade to ADD despite structural positives Our view Q4 performance was quite disappointing both on the growth and margin fronts despite price hikes taken given sequential market share losses in key brands Complan, Sugar Free and Nycil leading to an inferior product mix. Complan and Sugar Free continue to struggle since last few quarters due to category decline and less aggression in dis...
Add Zydus Wellness Ltd : Weakness persists on both growth and margin fronts; downgrade to ADD despite structural positives - Yes Securities
Weak execution; however, distribution (expansion) and product strategy (appears to be) in place Q3FY22 was a weak quarter with 2% YoY revenue growth (8.7% on 2-year CAGR basis). Product mix (inferior) and high raw material costs continued to impact margins – EBITDA margin shrank 467bps YoY to 8.3%. We continue to believe that the acquisition of Heinz India business is transformational for Zydus, given the increased consumer focus on health and wellness – likely accelerated c...
Buy Zydus Wellness Ltd For Target Rs.2,250 - ICICI Securities
Slower growth with trade inventory rationalisation About the stock: Zydus Wellness (ZWL) is one of the FMCG companies present in healthcare, nutrition & related products. The company has six brands i.e. Sugarfree, Complan, Glucon-D, Nycil, Everyuth & Nutrilite It commands dominant market share in sugar substitute (96%), prickly heat powder (34%) & glucose powder (58.1%) categories The company has more than 850 distributors with direct reach of 0.55 million retail outlets....
Buy Zydus Wellness Ltd For Target Rs.2200 - ICICI Direct
Highlights from the Quarter (Q3 FY22): The demand during the seasonally weak quarter was further affected by impact of third wave of the pandemic resulting into the muted top-line growth. The Management also cited inventory correction actions taken at the distributors’ level as one of the reasons for flat sales. Further, the inflationary pressure on key raw materials and packaging materials continued to put pressure on the gross margins resulting into weaker than expected operating l...
Buy Zydus Wellness Ltd Target Rs.2,520 - Sushil Finance
High commodity prices to keep margins under check About the stock: Zydus Wellness (ZWL) is one of the FMCG companies present in healthcare, nutrition & related products. The company has six brands i.e. Sugarfree, Complan, Glucon-D, Nycil, Everyuth & Nutrilite. * It commands dominant market share in sugar substitute (96%), prickly heat powder (34.5%) & glucose powder (58.3%) categories * The company has more than 1700 distributors with direct reach of 0.55 million retail o...
Buy Zydus Wellness Ltd For Target Rs.2800 - ICICI Direct
Margin headwinds remain but consistent double-digit growth delivery keeps us positive; maintain BUY Our view While Q2 performance was disappointing on the margins front, a strong 12% revenue growth with volume growth of 8% indicates strength of the brands and improved execution by the company. Consistent double-digit growth in Complan and Everyuth with market share gains and enhanced proposition launched during Q2 exhibits management’s focus to leverage the brand equity and furthe...
Buy Zydus Wellness Ltd For Target Rs.2,502 - Yes Securities
Zydus Wellness Ltd. recently announced its performance for the quarter ended September 30, 2021. Following are the key highlights Highlights from the Quarter (Q2 FY22): The second quarter of the fiscal which happens to be a seasonally weak quarter was further affected by poor season and limited consumer mobility because of second wave of covid. The glucose powder and prickly heat powder categories were particularly impacted by adverse weather condition and early monsoon. Nevertheless, s...
Buy Zydus Wellness Ltd For Target Rs.2,700 - Sushil Finance
Good 1QFY22 with improving margin trajectory (could've been better though) Q1FY22 was decent with broad-based growth across brands. Expansion in ecommerce and improving international business is positive. We continue to believe that the acquisition of Heinz India business is transformational for Zydus, given the increased consumer focus on health and wellness – likely accelerated consumer adoption of >70% of the portfolio (Sugar Free, Glucon-D, Nutralite and Complan). We es...
Buy Zydus Wellness Ltd For Target Rs.2,500 - ICICI Securities
Second Covid-19 wave drags sales… About the stock: Zydus Wellness (ZWL) is one of the FMCG companies present in healthcare, nutrition & related products. The company has six brands i.e. Sugarfree, Complan, Glucon-D, Nycil, Everyuth and Nutralite. * It commands a dominant market share in sugar substitute (93%), prickly heat powder (35.8%) & glucose powder (58.4%) categories. * The company has more than 1700 distributors with direct reach of 0.55 million retail outlets. ...
Buy Zydus Wellness Ltd For Target Rs.2800 - ICICI Direct
MTF Stock Pick Buy Zydus Wellness Ltd For Target Rs. 2586 - HDFC Securities TECHNICAL OBSERVATIONS ZYDUSWELL is in strong uptrend on Major time frame. After making a life high on 27th April 2021 it started correcting and halted near 1985 levels which also coincide with bullish trend line. Today stock has broken out from ascending triangle on the daily time frame which is bullish continuation pattern. It also took multiple support of bullish trend line and...
MTF Stock Pick Buy Zydus Wellness Ltd For Target Rs. 2586 - HDFC Securities
Leadership position in the key brands & consistent innovations to drive the growth: ZWL is an undisputed market leader in various niche categories such as sugar-substitutes (Sugar Free–93.0%), scrubs (Everyuth–35.8%), peel-offs (Everyuth– 77.0%), glucose powder (Glucon–D, 58.4%), prickly heat powder (Nycil–35.4%); 11 new products were launched during FY21. Widening geographical presence & share of overseas businesses: ZWL has planned to enter...
Buy Zydus Wellness Ltd For Target Rs.2,700 - Sushil Finance
Robust growth; margins to expand… Zydus Wellness (ZWL) reported healthy results with revenue growth of 24.2% due to ~| 100 crore sales loss in base quarter due to lockdown imposed in March 2020. The company witnessed strong double digit growth in Sugar Free & Nycil. Further, discretionary brand Everyuth also saw strong growth with an increase in out of home activity. HORECA dominant brand like Nutralite saw a sharp recovery with sales reaching at pre-Covid levels in Q4. ZWL m...
Buy Zydus Wellness Ltd For Target Rs. 2800 - ICICI Direct
Zydus and TLC, a specialty pharmaceutical company in Taiwan, today announced the signing of a license supply and commercialization agreement to commercialize AmphoTLC (Amphotericin B Liposome for Injection 50mg) in India. AmphoTLC is a critical drug to treat Mucormycosis or Black Fungus in India. Under the terms of the agreement, TLC will manufacture and supply AmphoTLC on a non-exclusive basis to Zydus, and Zydus will commercialize AmphoTLC in India. The Central Drugs Standard Control ...
Zydus & TLC sign agreement to market critical drug to treat Black Fungus
Symphony; retain top pick status Q4 performance was impressive with double digit-growth (on 2-year CAGR as well) across brands except for Glucon-D which was impacted due to delayed onset of summer season. We believe the acquisition of Heinz India business is transformational for Zydus, given the increased consumer focus on health and wellness – likely accelerated consumer adoption of >70% of the portfolio (Sugar Free, Glucon-D, Nutralite and Complan). We especially like the new...
Buy Zydus Wellness Ltd For Target Rs. 2,500 - ICICI Securities
Good 3Q; Broad-based performance Q3 witnessed continued growth as gross revenue grew 16% (volume-led), driven by broad-based strong brand performance. We believe the acquisition of Heinz India business is transformational for Zydus Wellness, given the increased consumer focus (COVID-led) on health and wellness – likely accelerated consumer adoption of >70% of the portfolio (Sugar Free, Glucon-D, Nutralite and Complan). We especially like – (1) the new product development st...
Buy Zydus Wellness Ltd For Target Rs.2,500 - ICICI Securities
Load More